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Abstract
Background: Recently it was shown that in Idiopathic Pulmonary Fibrosis (IPF) tissue infiltrating
CD8+ T lymphocytes (TLs) are associated with breathlessness and physiological indices of disease
severity, as well as that CD8+ TLs recovered by bronchoalveolar lavage (BAL) relate to those
infiltrating lung tissue. Since BAL is a far less invasive technique than tissue biopsy to study
mechanisms in IPF we further investigated the usefulness offered by this means by studying the
relationship between BAL macrophages, neutrophils, eosinophils, CD3+, CD4+, CD8+, CD8+/38+ TLs
and CD4+/CD8+ ratio with breathlessness and physiological indices.
Patients and methods: 27 IPF patients, 63 ± 9 years of age were examined. Cell counts were
expressed as percentages of total cells and TLs were evaluated by flow cytometry. FEV1, FVC, TLC,
RV, DLCO, PaO2, and PaCO2 were measured in all. Breathlessness was assessed by the Medical
Research Council (MRC) chronic dyspnoea scale.
Results: CD8+ TLs correlated positively (rs = 0.46, p = 0.02), while CD4+/CD8+ ratio negatively (rs
= -0.54, p = 0.006) with the MRC grade. CD8+ TLs correlated negatively with RV (rs = -0.50, p =
0.017). CD8+/38+ TLs were negatively related to the FEV1 and FVC (rs = -0.53, p = 0.03 and rs = -
0.59, p = 0.02, respectively). Neutrophils correlated positively with the MRC grade (rs = 0.42, p =
0.03), and negatively with the DLCO (rs = -0.54, p = 0.005), PaO2 (rs = -0.44, p = 0.03), and PaCO2
(rs = -0.52, p = 0.01).
Conclusion: BAL CD8+ TLs associations with physiological and clinical indices seem to indicate
their implication in IPF pathogenesis, confirming our previous tissue study.
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Background
In idiopathic pulmonary fibrosis (IPF) lung damage leads
to defects in mechanics and gas exchange and clinically
manifests with breathlessness on exertion[1]. Estimation
of breathlessness through the Medical Research Council
(MRC) chronic dyspnoea scale is easy to obtain and
appears to correlate well with physiological and radiolog-
ical indices of disease severity and extent in IPF patients
[2]. Physiological indices are easily available and highly
reproducible measurements providing the physician with
information regarding disease severity and extent and
more importantly their changes in time are reliable pre-
dictors of survival [3,4].
Several studies ascribe a role to the inflammatory cells
including neutrophils, macrophages, eosinophils and T
lymphocytes (TLs) in the modulation of tissue injury in
IPF [5-8]. Recently, we shown that in IPF tissue, infiltrat-
ing CD8+ TLs are associated with the grade of dyspnoea
and physiological indices of disease severity, implicating
that they might play a role in its pathogenesis[9], and also
that the CD8+ TLs recovered by bronchoalveolar lavage
(BAL) relate to those in lung tissue[10]. BAL is also of
value to study immune and inflammatory mechanisms in
IPF[11]. Investigations of tissue and BAL inflammatory
cells in IPF have shown that eosinophils, neutrophils and
CD8+ TLs are associated with tissue fibrosis [6-8,12]. CD8+
TLs in particular are associated with a worse prognosis
[13]. Since BAL is by far a less invasive technique than tis-
sue biopsy to study pathogenetic mechanisms in IPF we
further evaluated the usefulness offered by this means
studying the relationship between BAL macrophages, neu-
trophils, eosinophils, CD3+, CD4+, CD8+, CD8+/38+ TLs and
CD4+/CD8+ ratio with breathlessness and physiological
indices, in IPF patients.
Patients and Methods
Patients
Twenty-seven patients with IPF were included in the
study. Seventeen (65%) were male, and the mean (SD)
age of all patients was 63 (9) years. Two patients were cur-
rent smokers and nine were ex-smokers (>20 lifetime-
packs of cigarettes but cessation at least 3 months prior to
evaluation). They were recruited from the respiratory out-
patient clinic of the "Evangelismos" General Hospital,
Athens, Greece over a period of 5 years. The diagnosis of
UIP/IPF was based on standard criteria [14] which
included clinical findings (exertional dyspnoea, non-pro-
ductive cough, fine bibasilar inspiratory crackles), pulmo-
nary function tests (restrictive pattern and impaired gas
exchange), and high-resolution computerized tomogra-
phy findings (bibasilar honeycombing and reticular
abnormalities with minimal ground-glass opacities con-
sistent with the diagnosis of IPF). The diagnosis was con-
firmed by video-assisted thoracoscopic lung biopsy in
sixteen patients. Secondary causes of lung fibrosis were
excluded: none of the patients included in this study had
a history of environmental or occupational exposure, drug
toxicity or connective tissue disease, as documented by
patient's history and thorough clinical and immunologi-
cal work up. Both malignancy and infection were
excluded by careful cytology and microbiology examina-
tion of BAL fluid in all patients. The study is in compli-
ance with the Helsinki Declaration, was approved by the
Institutional Ethics Committee and informed consent was
obtained from each patient.
Pulmonary function tests
The pulmonary function tests included forced expiratory
volume in the first second (FEV1), forced vital capacity
(FVC), FEV1/FVC ratio ×100, total lung capacity (TLC),
residual volume (RV) and carbon monoxide transfer fac-
tor (DLCO). TLC and RV were measured by the helium
dilution method with a Master Screen apparatus (Erich
Jaeger GmbH, Wuerzburg, Germany), and DLCO by the
single breathholding helium dilution method [15,16].
Lung function measurements were expressed as percent-
ages of predicted values [15,16]. The arterial partial pres-
sure for oxygen (PaO2) and carbon dioxide (PaCO2) were
also measured at rest in all patients.
Dyspnoea
Dyspnoea was assessed with the modified (6 points) Med-
ical Research Council (MRC) dyspnoea scale score that
consists of six questions about perceived breathlessness
[17]: category 0, no dyspnoea; category 1, slight degree of
dyspnoea (troubled by shortness of breath when hurrying
on the level or walking up a slight hill); category 2, mod-
erate degree of dyspnoea (walks slower than people of the
same age on the level because of breathlessness); category
3, moderately severe degree of dyspnoea (has to stop
because of breathlessness when walking at own pace on
the level); category 4, severe degree of dyspnoea (stops for
breath after walking about 100 yards or after a few min-
utes on the level); category 5, very severe degree of dysp-
noea (too breathless to leave the house or breathless when
dressing or undressing).
Analysis of BAL cells
All patients underwent fiberoptic bronchoscopy under
light sedation before initiation of any kind of corticoster-
oid or immunosuppressive treatment. The videoscope
was wedged to a segmental bronchus of the right middle
lobe and lavage was performed using 20-ml aliquots of
warmed sterile normal saline (37°C) introduced by
syringe through the bronchoscopic aspiration port. A
fixed volume of 100–120 ml of saline solution was
infused sequentially. The recovered (bronchoalveolar lav-
age) BAL fluid was obtained through the same syringe and
placed on ice. BAL specimens were analyzed within 2 h ofJournal of Inflammation 2007, 4:14 http://www.journal-inflammation.com/content/4/1/14
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being collected. BAL was filtered through nylon sterile
gauze to remove mucus, pooled and the total volume was
measured. The total cell count was evaluated on an aliq-
uot of the pooled fluid using a Neubauer counting cham-
ber. Cell viability was determined by the trypan blue
exclusion test, and in all cases was higher than 90%. The
BAL fluid was centrifuged at 400 g, at 4°C, for 10 min. The
cell pellet was washed twice with cold phosphate buffered
saline (PBS) and resuspended in 4 ml RPMI 1640 medium
(Gibco; Grand Island, NY) supplemented with 10% (v/v)
heat-inactivated fetal bovine serum (FBS; Gibco; Grand
Island, NY). Differential cell counts were made on cyt-
ospin preparations. These were made by Shandon cyto-
centrifuge (Cytospin 3; Shandon Ltd, UK) using 100-μl
aliquots of the lavage cell suspensions, adjusted to 4 × 105
cells/ml. After fixation in methanol, slides were stained
with May-Grünwald-Giemsa stain. Differential counts
were made from a total count of 400 cells, excluding epi-
thelial cells, and were expressed as a percentage of the
total cell count.
Lymphocyte subsets in BAL were evaluated by multipa-
rameter analysis of leukocytes by flow cytometry [18]. Fol-
lowing gentle mixing, 100 μl of 0.5 × 106 BAL cells were
incubated with 10 μl of monoclonal antibody at 4°C for
20 min. For double colour analysis the antibodies were
conjugated with fluorescein isothiocyanate (FITC) or phy-
coerythrin (PE). The antibodies recognizing the following
antigens were used in pairs: CD2(FITC)/CD19(PE),
CD3(FITC)/CD4(PE), CD3(FITC)/CD8(PE) (Beckman
Coulter; France), CD45(FITC)/CD14(PE), CD3(FITC)/
CD16/CD56(PE), and CD8(FITC)/CD38(PE) (Becton-Dick-
inson; Belgium). CD8/CD38 positive cells were identified
only in those samples with an adequate number of total
cells (16 patients). In each analysis, cells stained by FITC-
and PE-conjugated isotype mouse-IgG were used as nega-
tive controls. Following incubation the red blood cells
were lysed (0.17 M NH4Cl lysis buffer) and the stained
cells washed with PBS, collected by centifugation and
resuspended in 1% paraformaldehyde.
The samples were analyzed using an ELITE ESP flow
cytometer (Coulter Electronics; FL, USA), which was
equipped with an argon laser providing an excitation
wavelength of 488 nm. Before measurement, the optical
path was adjusted by testing FlowChek (Beckman Coulter;
France). The result of one-half CV was in the range of less
than 2%. Data acquisition and analyses were performed
with the Elite workstation. A count cycle contained 10000
cells. Using a combination of CD45/CD14 and light-scatter
(FSC/SSC) characteristics, the lymphocytes were identi-
fied as small, non-alveolar cells with high CD45 expres-
sion.[18] Quadrant markers were set with the isotype
control to define the limits of non-specific fluorescence.
Measured subpopulations were expressed as percentages
of total lymphocytes.
Statistical Analysis
Data were expressed as means and standard error (SEM).
Since BAL cellularity was not normally distributed, corre-
lation coefficients were calculated using non parametric
Spearman's correlation coefficient. Furthermore for MRC
stepwise ordinal regression analysis was performed to
examine the independent effect of inflammatory cells
which were found to be significant in correlation analysis.
A P-value less than 0.05 was considered statistically signif-
icant. Analysis was performed using a SPSS/PC+ program.
Results
MRC chronic dyspnoea score and lung function data of all
patients are listed in Table 1. All patients claimed some
degree of dyspnoea (MRC score > 0) and most had a
restrictive lung function pattern characterized by a
decrease in TLC (mean value less than 65% of predicted)
and RV (mean value less than 64% of predicted). The
DLCO was also decreased in all patients (mean value was
less than 50% of predicted).
Table 2 presents the BAL data of the patients. Among the
inflammatory cells, lymphocytes appeared more numer-
ous than neutrophils and eosinophils. T lymphocytes
(CD3+ cells) were the main population of lymphocytes
accounting for 74.2% of total lymphocytes. CD4+ and
CD8+ subpopulations shared an almost identical percent-
age (35.8% and 35.9%, respectively), their ratio being 1.3
± 0.2.
Among all inflammatory cells studied, significant correla-
tions with clinical and pulmonary function parameters
are shown in Table 3. CD8+ TLs showed a positive correla-
tion with the MRC score (rs = 0.46, p = 0.02), while the
CD4+/CD8+ ratio correlated inversely (rs = -0.54, p = 0.006)
[Figures 1 and 2]. A negative correlation was also found
between CD8+ TLs and RV (rs = -0.50, p = 0.017). In the
subgroup of patients (n = 16) where the expression of the
markers CD8/CD38 was studied, a negative correlation
with FEV1 (rs = -0.53, p = 0.03) and FVC (rs = -0.59 and p
= 0.02) was found. The neutrophils showed a positive cor-
relation with MRC dyspnea score (rs = 0.42, p = 0.03) [Fig-
ure 3], and negative correlation with the DLCO (rs = -0.54,
p = 0.003), PaO2 (rs = -0.44, p = 0.03), and PaCO2 (rs = -
0.52, p = 0.01). No significant correlations could be iden-
tified among the MRC chronic dyspnoea score or lung
function parameters and the other cell populations.
The multiple ordinal regression analysis showed that
CD8+ cells was the only BAL parameter that was signifi-
cantly related with the MRC dyspnea score, when adjust-Journal of Inflammation 2007, 4:14 http://www.journal-inflammation.com/content/4/1/14
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ing for the effect of the neutrophils and the CD4+/CD8+
ratio. (p = 0.042).
Discussion
Based on recent studies showing that infiltrating mono-
nuclear cells and especially CD8+ TLs could be implicated
in the pathogenesis of IPF and the observation that in IPF
the TL subpopulations recovered by BAL relate to those in
lung tissue [9,10], we further evaluated the relationships
between BAL cells and physiologic and clinical parameters
of disease severity in IPF patients. Among the different
inflammatory cells studied, CD8+ TLs correlated positively
with the MRC chronic dyspnoea grade and negatively with
RV, while the CD4+/CD8+ ratio correlated negatively with
the MRC chronic dyspnea grade. Activated CD8+/38+ TLs
correlated negatively with the FEV1 and FVC. Furthermore,
neutrophils correlated positively with the MRC dyspnea
grade and negatively with DLCO, PaO2, and PaCO2.
Associations found in the present study were significant
but moderate in comparison to those found between cell
subsets in tissue biopsy and the same clinical and physio-
logical parameters [9]. These findings readdress the issue
of whether the BAL cellular profile may become a valuable
tool to study pathogenetic mechanisms in this group of
patients. Furthermore they reinforce the already existing
discrepancies on the pathogenetic role of inflammatory
cells in IPF patients. Although the current pathogenetic
theories in IPF sustain progress despite paucity of intersti-
tial inflammation, the role of inflammatory response in
the modulation of tissue injury and fibrosis still remains
under investigation [19,20].
In the present study among all inflammatory cells studied
in BAL fluid, significant associations were only found for
CD8+ TLs, activated CD8+ TLs and neutrophils implicating
some role in the pathogenetic mechanism of IPF. In the
present study, the lymphocyte count was found to be less
than 12%. Compared with BAL constituents in healthy
non-smoker individuals, this value belongs to the normal
range of lymphocytosis calculated in normal historical
controls [21]. This is in accordance with previous studies
in well documented UIP/IPF patients, demonstrating
mean lymphocyte counts ranging from 8.5–16.4% in this
Table 1: Clinical and pulmonary function data* of the study population (n = 27)
MRC score 2.2 ± 0.2 (1–4)
FEV1 (% pred) 80.1 ± 2.9 (57–107)
FVC (% pred) 74.7 ± 2.8 (55–99)
FEV1/FVC × 100 (ratio) 85.9 ± 1.5 (71–100)
TLC (% pred) 64.5 ± 2.7 (46–96)
RV (% pred) 63.8 ± 5.8 (35–150)
DLCO (% pred) 48.9 ± 3 (17–80)
PaO2 (mmHg) 73.0 ± 1.95 (53–89)
PaCO2 (mmHg) 36.7 ± 0.86 (29–45)
*Values are means ± SEM (with ranges in parentheses).
Table 2: Analysis of the differential cell profile in BAL from study population, (n = 27)
Differential cell counts
Total BAL cell count ×103/ml of recovered BAL§ 134.7 ± 13.6
Macrophages * 82.2 ± 2.7
Neutrophils * 6.8 ± 1.8
Eosinophils * 2.6 ± 0.6
Lymphocytes * 9.1 ± 1.9
Lymphocyte phenotypes
CD2-/CD19+ cells **(B lymphocytes) 1.9 ± 0.3
CD3+/CD16+CD56+**(cytotoxic lymphocytes) 2.8 ± 0.5
CD3-/CD16+CD56+ **(natural killer cells) 4 ± 0.6
CD3+ cells ** (TLs) 74.2 ± 4.6
CD4+ cells **(helper TLs) 35.8 ± 3. 9
CD8+ cells **(cytotoxic/suppressor TLs) 35.9 ± 3.9
CD8+/38+ cells **(activated CD8+ cells) (n = 16) 4.0 ± 0.8
CD4+/CD8+ ratio 1.3 ± 0.2
Values are means ± SEM (with ranges in parentheses). § The mean value of recovered BAL is 55.6% with a range of 41.6% to 80% *Values are 
expressed as percentages of total BAL cell count. ** Values are expressed as percentage of total lymphocytes.Journal of Inflammation 2007, 4:14 http://www.journal-inflammation.com/content/4/1/14
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group of patients [12,22,23]. The clinical value of CD4+/
CD8+ ratio and of CD8+ positive lymphocytes exists even in
cases with normal lymphocytes count and has been
already described both in sarcoidosis and in IPF [12,22].
More precisely, Welker et al demonstrated that even in
cases with low percentages of lymphocytes, an elevated
CD4+/CD8+ ratio raises the likelihood for sarcoidosis to
more than 85% [22]. As far as IPF patients are concerned,
Fireman et al, showed that a lower ratio of CD4+/CD8+ and
a higher number of cytotoxic CD8+ cells predicted a worse
response to treatment [13]. Therefore subtyping of CD4+
and CD8+ TLs could be performed even in BAL without
severe lymphocytosis.
Regarding CD8+ TLs, tissue studies have shown that they
infiltrate sites of tissue damage [24], and other studies in
BAL have shown that they may also be associated with a
worse prognosis [12,13]. In scleroderma lung fibrosis, for
instance, CD8+ TLs are associated with progressive fibrosis
resembling more patients with IPF [25]. Recently we
observed that tissue CD8+ TLs correlated significantly with
physiological and clinical indices of disease severity [9].
The exact mechanisms through which CD8+ TLs contrib-
ute to lung injury and pulmonary fibrosis are not yet clear.
The current hypothesis on the development of IPF con-
ceptualizes ongoing, multiple, small focal episodes of epi-
thelial lung injury followed by a pathologic fibrotic repair
mechanism and an imbalance in the expression of T-
helper type 1 (Th1) and Th2 cytokines [5,26] CD8+ TLs are
known to produce type 2 cytokines such as interleukin-4
and interleukin-5 [27]. Recently, it has been hypothesized
that in patients with IPF an excessive recruitment of CD8+
TLs may occur in response to repeated viral infections and
this excessive response may play a role in the develop-
ment of lung damage through multiple mechanisms
(nuclear factor κB, tumor necrosis factor α) of epithelial
cells activation, production of chemokines by the alveolar
cells which may in turn amplify inflammatory responses
in the lung [28]. Furthermore activated CD8+ TLs express
high levels of CD38, a molecule involved in "homing in"
of inflammatory cells and cytokine production [29]. Neu-
trophils, on the other hand, may play a critical role in the
induction of lung injury through their capacity to secrete
collagenases and other proteolytic enzymes including
neutrophils' elastase that degrade different types of colla-
gen and to release oxidants such as superoxide and hydro-
gen peroxide that damage tissue cells [30].
As far as BAL is concerned, its role in evaluating diffuse
parenchymal lung disease remains under investigation.
The technique is safe and minimally invasive. In addition
lavage samples a much larger area of the lungs that can be
obtained by biopsy specimens [11]. In IPF patients it is
considered a requirement for the exclusion of other dis-
eases, when biopsy is not performed [14]. Its prognostic
importance has been highlighted in interstitial lung dis-
ease other than IPF, such as NSIP and scleroderma fibrosis
[22,25].
In IPF results are rather controversial. Some studies have
shown correlations for at least some of the cell popula-
Relationship between BAL CD8+ cells and MRC dyspnea  score in IPF patients Figure 1
Relationship between BAL CD8+ cells and MRC dyspnea 
score in IPF patients.
Table 3: Significant correlations of differential cell counts with clinical and pulmonary function parameters.
MRC score RV FEV1 FVC DLCO PaO2 PaCO2
CD8+TLs rs = 0.46 
(p = 0.023)
rs = -0.50 
(p = 0.017)
--- --
CD4+/CD8+TLs rs = -0.54 
(p = 0.006)
-- - -- -
CD8+/38+TLs -- r s = -0.53 
(p = 0.032)
rs = -0.59 
(p = 0.02)
-- -
Neutrophils rs = 0.42 
(p = 0.032)
-- - r s = -0.54 
(p = 0.005)
rs = -0.44 
(p = 0.033)
rs = -0.52 
(p = 0.01)Journal of Inflammation 2007, 4:14 http://www.journal-inflammation.com/content/4/1/14
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tions studied between BAL and tissue biopsy in the same
patients [10,13] and some have not [31]. According to the
results of the present study, BAL findings seem to reflect
associations between cellular, physiological and clinical
parameters developed in previous studies, based on tissue
biopsies in well documented groups of UIP/IPF patients
[9,12,13,22]. Based on our results, we believe that BAL
could be reliably used to assess patients with IPF, not only
to exclude infection, malignancy and other interstitial
lung diseases but also to unravel the role of inflammatory
cells in the pathogenesis of pulmonary fibrosis.
Conclusion
BAL CD8+ TLs associations with physiological and clinical
indices seem to indicate their implication in IPF patho-
genesis, confirming our previous tissue study.
Based on the non-invasiveness of BAL application, on the
quality of information that this tool provides to clinicians
on interstitial/alveolar lung milieu and on the recently
developing tendency to obviate lung biopsy and to rely
more on non invasive methods for diagnosis and follow-
up of the disease, [11,32] we conclude that BAL analysis is
of importance in evaluating the pathogenetic mechanisms
in UIP/IPF patients.
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